Market Newsdesk

Genius Sports’ FANHub Platform Powers Award-Winning Indy 500 Marketing Partnership with EchoPoint Media

• Partnership renewed after exceeding ticket sales goals
• New campaigns to use advanced segmentation strategies and dynamic creative

NEW YORK–(BUSINESS WIRE)–
Genius Sports Limited (“Genius Sports”) (NYSE:GENI) and EchoPoint Media today announced the renewal of their media partnership to promote the 2025 Indianapolis 500, one of the most iconic events in motorsports. The collaboration will build upon the innovative, data-powered marketing strategies that drove unprecedented sales for the race in 2024.

The renewed partnership comes after Genius Sports’ campaign for the 2024 Indy 500 was recognized in the Sports category at The Drum Awards, honoring the best work in the marketing and advertising industry. The campaign leveraged Genius Sports’ proprietary data and audience targeting capabilities to deliver ticket sales at a rate 45% more efficient than previous benchmarks.

“After the exceptional results and industry recognition our partnership garnered last year, renewing with Genius Sports was an easy decision,” said Hannah Lane, Senior Media Supervisor at EchoPoint Media. “Their unique ability to translate complex sports data into tangible marketing results gives us confidence that we’ll continue to connect with passionate racing fans and drive ticket sales for this year’s Indianapolis 500.”

The 2024 campaign stood out for its innovative use of Genius Sports’ motorsports data and real-time countdown clocks in ad creative, creating urgency that accelerated purchase decisions. The renewed partnership will expand on last year’s approach, incorporating first-party data, targeted audience insights, and contextual placements to reach motorsports enthusiasts across NASCAR, Formula 1, and other racing disciplines.

“We’re honored to continue our work with EchoPoint and such an important sporting event as the Indy 500,” said Josh Linforth, Chief Revenue Officer at Genius Sports.

“Our data-driven approach consistently delivers measurable results. For 2025, we’re enhancing our strategy with even more sophisticated audience segmentation and dynamic creative capabilities to build on last year’s success.”

The 109th Running of the Indianapolis 500 is scheduled for Sunday, May 25, 2025.

About Genius Sports

Genius Sports is the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media. Our technology is used in over 150 countries worldwide, creating highly immersive products that enrich fan experiences for the entire sports industry.

We are the trusted partner to over 400 sports organizations, including many of the world’s largest leagues and federations such as the NFL, EPL, FIBA, NCAA, NASCAR, AFA and Liga MX.

Genius Sports is uniquely positioned through cutting-edge technology, scale and global reach to support our partners. Our innovative use of big data, computer vision, machine learning, and augmented reality, connects the entire sports ecosystem from the rights holder all the way through to the fan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403392414/en/

Media Contacts:

Chris Dougan, Chief Communications Officer

+1 (202) 766-4430

[email protected]

KEYWORDS: United States North America Indiana New York

INDUSTRY KEYWORDS: Sports Entertainment Professional Services Events/Concerts Motor Sports Licensing (Sports) Data Management Technology Digital Marketing Data Analytics Marketing Advertising Communications

MEDIA:

Logo

Lineage to Report First-Quarter 2025 Financial Results on April 30, 2025

NOVI, Mich.–(BUSINESS WIRE)–
Lineage, Inc. (NASDAQ: LINE), announced that it will report its financial results for the first quarter of 2025 on Wednesday, April 30, 2025, before market open. A conference call to discuss these results has been scheduled for 8:00 a.m. Eastern Time on Wednesday, April 30, 2025.

A live webcast of the call will be available on the Lineage Investor Relations website at ir.onelineage.com. An audio replay of the conference call will be available for one week following the call and archived via webcast on the Lineage Investor Relations website at ir.onelineage.com for approximately one year.

About Lineage

Lineage, Inc. (NASDAQ: LINE) is the world’s largest global temperature-controlled warehouse REIT with a network of over 485 strategically located facilities totaling approximately 86 million square feet and approximately 3.1 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us on LinkedIn, Facebook, Instagram, and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403719085/en/

Investor Relations Contact

Evan Barbosa

VP, Investor Relations

[email protected]

Media Contact

Megan Hendricksen

VP, Global Marketing & Communications

[email protected]

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Supply Chain Management Retail Construction & Property REIT

MEDIA:

Logo

Redfin Reports Spring Brings Record-High Monthly Housing Costs, Keeping Pending Home Sales at Bay

Soaring housing payments are keeping many homebuyers on the sidelines, but new listings are ticking up and there are signs some house hunters are emerging as spring begins

SEATTLE–(BUSINESS WIRE)–
(NASDAQ: RDFN) — The typical U.S. homebuyer’s monthly payment hit a record high for the second week in a row, reaching $2,802 during the four weeks ending March 30. That’s according to a new report from Redfin (redfin.com), the technology-powered real estate brokerage. Sale prices are up 3.4% year over year, and the weekly average mortgage rate is 6.65%, near its lowest level since December but more than double pandemic-era lows.

Pending home sales are declining. High costs are keeping a lid on sales; pending home sales fell 2.3% year over year.

But there are signs more house hunters are hitting the pavement. Mortgage-purchase applications are at their highest level in over two months. Home tours are rising twice as fast this year than they were at this time last year (though that’s partly because Easter fell into last year’s comparable period). Finally, Google searches of “homes for sale” are up to their highest level since August. Redfin agents report many prospective buyers have made peace with elevated rates and prices, and those who can afford to buy are moving forward before costs increase more.

New listings are rising. New listings of homes for sale rose 12.7% year over year during the four weeks ending March 30, the biggest increase in 11 months. That’s partly because some sellers are hoping to cash in on high prices and some are noticing increased interest from house hunters: Easter fell into the comparable period in 2024, while the holiday hasn’t yet hit this year.

“Supply is picking up; a lot of people I’ve spoken to over the last year or two are calling, saying they’re ready to list their house,” said Matt Ferris, a Redfin Premier agent in northern Virginia. “Some believe we’re at the top of the market, and they want to get top dollar for their house. Some are moving for the usual reasons: They need a bigger home, they’re retiring, or they’re relocating to a different area. And here in the D.C. area, some people are selling because they’re worried about losing their government job, or because they want to buy closer to the city due to in-office policies.”

For Redfin economists’ takes on the housing market, please visit Redfin’s “From Our Economists” page.

Leading indicators
Indicators of homebuying demand and activity
	Value (if applicable)	Recent change	Year-over-year change	Source
Daily average 30-year fixed mortgage rate	6.72% (April 2)	Down from 6.82% a week earlier; near lowest level since early December	Down from 7.07%	Mortgage News Daily
Weekly average 30-year fixed mortgage rate	6.65% (week ending March 27)	Down marginally from the week before; near lowest level since mid-December	Down from 6.79%	Freddie Mac
Mortgage-purchase applications (seasonally adjusted)		Up 2% from a week earlier (as of week ending March 28)	Up 9%	Mortgage Bankers Association
Touring activity		Up 37% from the start of the year (as of March 31)	At this time last year, it was up 16% from the start of 2024	ShowingTime, a home touring technology company
Google searches for “home for sale”		Up 17% from a month earlier (as of March 31)	Up 4%	Google Trends
The Redfin Homebuyer Demand Index has been excluded this week to ensure data accuracy.

Key housing-market data
U.S. highlights: Four weeks ending March 30, 2025 Redfin’s national metrics include data from 400+ U.S. metro areas, and are based on homes listed and/or sold during the period. Weekly housing-market data goes back through 2015. Subject to revision.
	Four weeks ending March 30, 2025	Year-over-year change	Notes
Median sale price	$386,019	3.4%
Median asking price	$424,975	6.7%
Median monthly mortgage payment	$2,802 at a 6.65% mortgage rate	5.2%	Record high
Pending sales	85,402	-2.3%	Smallest decline since start of 2025
New listings	100,366	12.7%	Biggest increase in 11 months
Active listings	981,872	11.7%
Months of supply	4.1	+0.7 pts.	4 to 5 months of supply is considered balanced, with a lower number indicating seller’s market conditions
Share of homes off market in two weeks	38.5%	Down from 42%
Median days on market	45	+6 days
Share of homes sold above list price	24.6%	Down from 28%
Average sale-to-list price ratio	98.6%	Down from 98.9%

Metro-level highlights: Four weeks ending March 30, 2025 Redfin’s metro-level data includes the 50 most populous U.S. metros. Select metros may be excluded from time to time to ensure data accuracy.
	Metros with biggest year-over-year increases	Metros with biggest year-over-year decreases	Notes
Median sale price	Cleveland (10.4%) Nassau County, NY (10%) Newark, NJ (9%) Chicago (7.8%) New Brunswick, NJ (7.3%)	Jacksonville, FL (-4.6%) Tampa, FL (-1.7%) Dallas (-1.4%) Atlanta (-0.6%) Orlando, FL (-0.4%) Portland, OR (-0.3%)	Declined in 6 metros
Pending sales	Montgomery County, PA (10.1%) Pittsburgh (4.6%) Cincinnati (3.7%) Denver (3%) Phoenix (2%)	Fort Lauderdale, FL (-15.8%) Miami (-15.1%) Las Vegas (-13.7%) Columbus, OH (-12.3%) Houston (-11.4%)	Increased in 11 metros
New listings	Denver (29.1%) Montgomery County, PA (28.1%) Phoenix (26%) Washington, D.C. (26%) Boston (23.1%)	San Antonio (-4.8%) Columbus, OH (-1.6%)	Declined in 2 metros

To view the full report, including charts, please visit:

https://www.redfin.com/news/housing-market-update-costs-record-high-new-listings-increase.

About Redfin

Redfin (www.redfin.com) is a technology-powered real estate company. We help people find a place to live with brokerage, rentals, lending, and title insurance services. We run the country’s #1 real estate brokerage site. Our customers can save thousands in fees while working with a top agent. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Our rentals business empowers millions nationwide to find apartments and houses for rent. Since launching in 2006, we’ve saved customers more than $1.8 billion in commissions. We serve approximately 100 markets across the U.S. and Canada and employ over 4,000 people.

Redfin’s subsidiaries and affiliated brands include: Bay Equity Home Loans®, Rent.™, Apartment Guide®, Title Forward® and WalkScore®.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403415242/en/

Contact Redfin

Redfin Journalist Services:

Tana Kelley

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Professional Services Technology Residential Building & Real Estate Finance Construction & Property Internet

MEDIA:

Logo

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Management Available for One-to-One Meetings

PONTE VEDRA, Fla.–(BUSINESS WIRE)–Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company’s commitment to advancing innovation and clinical development in anticoagulation therapy.

Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18^th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy.

Additionally, Dr. Ferguson will attend the 13th annual CMO Summit 360° ^® taking place on April 7-8, the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels, and geographic locations.

Expanding its industry and business development engagement, the Company will be at the BIO International Convention, the world’s largest biotechnology conference, from June 16-19, 2025 in Boston, MA, to meet with potential partners and collaborators to advance and enhance our lead program, tecarfarin and to build our pipeline in specialized cardiovascular therapeutics.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel, and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. Although warfarin is widely used off-label for several rare cardiovascular conditions, extensive clinical and real-world data have shown it to have significant serious side effects. With tecarfarin, Cadrenal aims to meet the unmet needs of these patient populations by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges.

Cadrenal is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).

Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403821539/en/

Corporate and Investor Relations

Lisa DeScenza

LaVoieHealthScience

(978) 395-5970

[email protected]

Media

Andrew Korda

LaVoieHealthScience

(617) 865-0043

[email protected]

KEYWORDS: United States North America Florida Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Cardiology

MEDIA:

Logo

Newegg Confirms Effective Date of Share Combination

DIAMOND BAR, Calif.–(BUSINESS WIRE)–
Newegg Commerce, Inc. (NASDAQ: NEGG) (the “Company”), a global leader in e-commerce for technology products, today announced that the twenty-to-one share combination (commonly referred to as a reverse stock split) of its common shares will become effective on April 7, 2025 upon the filing of the Amended and Restated Memorandum and Articles of Association with the Registry of Corporate Affairs in the British Virgin Islands, which will result in a proportionate increase to the par value of the Company’s common shares from $0.021848 per share to $0.43696 per share. As previously announced, the share combination was approved by the Company’s board of directors and the controlling shareholders of the Company by written consent. While the CUSIP number for the Company’s common shares will change from G6483G 100 to G6483G 209, the common shares will continue to trade on the Nasdaq Capital Market under the symbol “NEGG.” The share combination is intended to enable the Company to continue to meet minimum Nasdaq listing price per share requirements and will affect all shareholders proportionately. The share combination will not alter any shareholder’s percentage interest in the Company, except for fractional shares created by the share combination, which will be exchanged for cash.

The Company’s transfer agent, Computershare Inc. (“Computershare”), is acting as the exchange and paying agent for the share combination. Registered holders are encouraged to contact Computershare and beneficial holders are encouraged to contact their bank, broker or other nominee with any questions.

About Newegg

Newegg Commerce, Inc. (NASDAQ: NEGG), founded in 2001 and based in Diamond Bar, Calif., near Los Angeles, is a leading global online retailer for PC hardware, consumer electronics, gaming peripherals, home appliances, automotive and lifestyle technology. Newegg also serves businesses’ e-commerce needs with marketing, supply chain, and technical solutions in a single platform. For more information, please visit Newegg.com.

Follow Newegg on X, TikTok, Instagram, Facebook, YouTube, Twitch, Threads and Discord.

Cautionary Statement Concerning Forward-Looking Statements

This news release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations, opinion, belief or forecasts of future events and performance. A statement identified by the use of forward-looking words including “will,” “intends,” and certain other statements about the future may be deemed forward-looking statements. All statements, other than statements of historical facts included in this press release, including statements concerning the timing of implementation of the share combination, and the Company’s intentions and expected benefits associated therewith, are forward-looking statements. Although Newegg believes that the expectations reflected in such forward-looking statements are reasonable at the time given, these statements involve risks and uncertainties that may cause actual future activities and outcomes to be materially different from those suggested or described in this news release. These risks and uncertainties include changes in global economic and geopolitical conditions, fluctuations in customer demand and spending, inflation, interest rates and global supply chain constraints. Investors are cautioned that any forward-looking statements are not guarantees of future outcomes or developments may differ materially from those projected. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company’s SEC filings are available at http://www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403927568/en/

Newegg Commerce, Inc.:

Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Public Relations/Investor Relations Communications Software Hardware Retail Data Management Consumer Electronics Online Retail

MEDIA:

Logo

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US ¹ impacted by these conditions and opens new opportunities for GeneDx and biopharma partners to accelerate the path to treatment for patients

GAITHERSBURG, Md.–(BUSINESS WIRE)–
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the commercial expansion into Inborn Errors of Immunity (IEI), a group of nearly 500 genetic disorders that impair immune function², increasing susceptibility to infections, autoimmunity, and inflammatory conditions. The strategic expansion reinforces GeneDx’s mission to improve patient outcomes by providing exome and genome testing solutions for an ever-growing number of patients, now including those with inherited immunological conditions.

With an expanded commercial focus on IEIs, GeneDx accelerates patient care with the adoption of exome and genome testing, empowering ordering clinicians with more accurate and comprehensive genetic insights to better treat this patient population. Today, clinicians treating IEIs recognize the importance of genetic testing, and with the rapid pace of new gene-disease discovery in IEI¹, exome and genome sequencing are better equipped than panel-based testing to stay up to date with new discoveries in this area. Genomic sequencing provides a diagnostic yield of approximately 40% for IEI patients^3,4,5 — higher than the 29% yield from multi-gene panels.³

With superior diagnostic accuracy and growing reimbursement support, the shift toward an exome and genome-first approach accelerates times to an accurate diagnosis and informs personalized treatment decisions such as bone marrow transplantation, gene therapy, biologic supportive therapy, and Ig replacement therapy. Therapies are available for more than 50% of individuals with an IEI.⁶

“GeneDx’s commercial focus on Inborn Errors of Immunity furthers our commitment to providing patients, families and clinicians with the most comprehensive genetic testing solutions at the times they need it most,” said Britt Johnson, PhD, FACMG, and Senior Vice President of Medical Affairs at GeneDx. “By transitioning from panel-based testing to exome and genome sequencing, GeneDx will improve diagnostic precision, enabling earlier interventions, and ultimately enhancing patient outcomes by accelerating the path to treatment.”

In the past 18 months, GeneDx has sequenced more than 5,000 patients suspected of having IEIs. This commercial and patient focus not only empowers providers with comprehensive genetic insights to deliver optimal patient care but also opens new opportunities for biopharma partners to advance research, drug discovery, and therapeutic development by leveraging GeneDx’s industry-leading dataset of more than 750,000 clinical exomes and genomes already enriched with IEI data.

“Inborn Errors of Immunity can be difficult to diagnose based on clinical features alone due to complex and overlapping phenotypes. Comprehensive exome and genome sequencing enable precise diagnoses and allow patients to access clinical trials and targeted therapies that may improve their quality of life and clinical outcomes,” said Heather McLaughlin, PhD, FACMG and Senior Director, Molecular Diagnostics at Pharming.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (vi) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

References:

1.	Rider, NL, Truxton A, Ohrt T, et al. Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data. J Allergy Clin Immunol. 2024 Jun;153(6):1704-1710. doi: 10.1016/j.jaci.2024.01.011. Epub 2024 Jan 24.
2.	Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022 Oct;42(7):1473-1507. doi: 10.1007/s10875-022-01289-3
3.	Vorsteveld EE, Hoischen A, van der Made CI. Next-Generation Sequencing in the Field of Primary Immunodeficiencies: Current Yield, Challenges, and Future Perspectives. Clin Rev Allergy Immunol. 2021 Oct;61(2):212-225. doi: 10.1007/s12016-021-08838-5.
4.	Chen Y, Li D, Yin J, et al. Diagnostic yield of next-generation sequencing in suspect primary immunodeficiencies diseases: a systematic review and meta-analysis. Clin Exp Med. Jun 18 2024;24(1):131. doi:10.1007/s10238-024-01392-2
5.	Platt CD, Zaman F, Bainter W, et al. Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency. J Allergy Clin Immunol. Feb 2021;147(2):723-726.
6.	Quinn J, Modell V, Johnson B, Poll S, Aradhya S, Orange JS, Modell F. Global Expansion of Jeffrey’s Insights: Jeffrey Modell Foundation’s Genetic Sequencing Program for Primary Immunodeficiency. Front Immunol. 2022 Jun 10;13:906540. doi: 10.3389/fimmu.2022.906540.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403427991/en/

Investor Relations Contact:

[email protected]

Media Contact:

[email protected]

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Biotechnology Managed Care Health General Health Healthcare Reform Pharmaceutical Medical Devices Hospitals Genetics Public Policy/Government Clinical Trials

MEDIA:

Logo

A New Frontier in Radios: Rocket Lab Announces Expanded Radio Products for Reliable Command and Control

LONG BEACH, Calif.–(BUSINESS WIRE)–
Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today introduced its expanded suite of space-grade radio frequency (RF) communications systems, the Frontier radios. The Frontier radio is flight-proven, software-defined and designed for reliable telemetry, tracking, and command (TT&C).

Adapted from the Johns Hopkins University Applied Physics Laboratory’s Frontier Lite radio, Rocket Lab’s high-performance Frontier radios have over 13 years of flight heritage and are now available in L-, S-, C-, X-, and Ka-band models. The radio is designed from the ground up for reliable and secure communications to support any orbit or space environment and have advanced capabilities like ranging waveforms for radiometric navigation. Frontier radios are compact and lightweight for easy integration onto any satellite.

As part of Rocket Lab’s vertically integrated subsystems and components, Frontier radios are compatible with the Deep Space Network and other global ground stations, including the Near Earth Network, Air Force Satellite Control Network, KSAT, SSC, Viasat, and other commercial networks.

“We are excited to add this suite of software-defined radios to our expanding portfolio of products,” said Brad Clevenger, Vice President of Rocket Lab Space Systems. “We continue to demonstrate our ability to deliver high reliability, high performance products at constellation scale. While much of the industry struggles with supply chain challenges, Rocket Lab continues to demonstrate that it is the right partner for merchant component supply to the most demanding missions.”

This RF product suite is a further expansion of Rocket Lab’s component products, joining a portfolio that includes reaction wheels, star trackers, solar power systems, flight software, ground software, separation systems, and more.

Frontier radios are flight-proven across a range of missions including Rocket Lab’s Photon Pathstone, three Rocket Lab Pioneer spacecraft for Varda Space Industries, NASA’s CAPSTONE, NASA’s Europa Clipper, NASA’s Solar Probe Plus, Emirates Mars, and Van Allen Probes. Upcoming, Rocket Lab’s Frontier L-band radio will be used for Viasat to support their hybrid space communications network demonstrations for NASA’s Communications Services Project.

The Frontier Radio was also selected as a 2024 R&D 100 Award for innovations pushing the boundaries of research and development.

+ About Rocket Lab

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered more than 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit www.rocketlabusa.com.

+ Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403572210/en/

+ Rocket Lab Media Contact

Lindsay McLaurin

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Satellite Aerospace Manufacturing Software Hardware

MEDIA:

Logo

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

• CREXONT added to 3 large national formularies: Veterans Administration, UnitedHealthcare and CVS Health
• Increases insurance coverage to over 50% of covered lives
• CREXONT was approved by the U.S. FDA to treat Parkinson’s disease in 2024

BRIDGEWATER, N.J.–(BUSINESS WIRE)–
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that three large insurance coverage accounts, the Veterans Administration (VA), UnitedHealthcare and CVS Health, have added CREXONT^® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD) to their national prescription drug formularies. CREXONT is a prescription medication for the treatment of PD approved by the U.S. FDA in August 2024.

This expanded coverage increases CREXONT’s total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%. The Company had initially set a goal to surpass 50% coverage by the end of 2025, making this milestone—achieved nine months ahead of schedule—a testament to Amneal’s commitment to broadening patient access. The VA has already added the product in its national formulary, covering approximately 10% of U.S. PD patients. UnitedHealthcare will add CREXONT to its standard prescription drug lists in the second quarter of 2025. In addition, CVS Health will add CREXONT as a “preferred” product to its national formulary on July 1, 2025.

“We are extremely proud to announce the addition of CREXONT on three major insurance platforms,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty at Amneal Pharmaceuticals. “Achieving over 50% coverage within just six months of launch is a significant milestone, demonstrating the immense value CREXONT offers PD patients and our continued commitment to ensuring patient access.”

CREXONT’s therapeutic benefits include:

• Novel formulation designed to provide long lasting efficacy: CREXONT is an innovative formulation of carbidopa/levodopa (CD/LD) that combines immediate-release (IR) granules for rapid onset of action and extended-release pellets with a novel technology, designed to target the area of absorption, making CREXONT the longest-lasting oral CD/LD formulation available today. The novel technology delivers more stable levodopa levels that do not wear off as quickly or as often as traditional IR formulation. Over time with IR CD/LD therapy, the duration of symptom control may become more unpredictable, and patients may experience more “Off” time. About half of patients taking a PD medication may experience “Off” episodes – time where their motor symptoms return or are not well-controlled – within 2 to 3 years of treatment initiation.¹
• More “Good On” time with less frequent dosing: A head-to-head clinical trial showed CREXONT provides more “Good On” time per day, and 1.55 more hours of “Good On” time per dose (where symptoms are well-controlled without troublesome involuntary movements) compared to IR CD/LD. This represents a 70% increase in the amount of time each dose helps people feel in control of their PD symptoms.
• Safety profile consistent with IR CD/LD: The most common adverse reactions with CREXONT (incidence ≥3% and greater than IR CD/LD) are nausea and anxiety. See Important Safety Information below.

To further support patients, providers, and care partners as they navigate insurance coverage and their treatment on CREXONT, Amneal offers a full suite of services and support within the Amneal Patient Support Program. For more information, visit https://crexont.com/support-resources/ or call 1-877-764-9021 Monday-Friday 8:00AM-5:00PM CST for live support.

About CREXONT^®

CREXONT is an innovative formulation consisting of immediate-release granules with carbidopa and levodopa for rapid onset of action, and extended-release pellets with levodopa for long-lasting efficacy. CREXONT formulation and dosage strengths are different from RYTARY^® (carbidopa and levodopa) extended-release capsules approved by the U.S. FDA in 2015. Learn more about CREXONT at crexont.com.

INDICATION

CREXONT (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

• Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.
• Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.
• CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery, until you know how CREXONT affects you.
• The most common side effects that may occur with CREXONT are nausea and anxiety.
• Avoid sudden discontinuation or rapid dose reduction with CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.
• You may take CREXONT with or without food; but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.
• Swallow CREXONT whole. Do not chew, divide, or crush the capsules.
• Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

• Have any heart conditions, especially if you have had a heart attack or irregular heartbeats.
• Experience hallucinations or abnormal thoughts and behaviors.
• Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges.
• Have thoughts of suicide or have attempted suicide.
• Have abnormal involuntary movements that appear or get worse during treatment.
• Have ever had a peptic ulcer or glaucoma.
• Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm.
• Are breastfeeding during therapy.
• Have side effects; your doctor can adjust your dose.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

References:

(1) Stocchi F et al. Parkinsonism Relat Disord. 2014;20(2):204-211.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403876544/en/

Investor Contact

Anthony DiMeo

VP, Investor Relations

[email protected]

Media Contact

Randi Kahn

SVP, Corporate Affairs, Syneos Health

[email protected]

Amneal Medical Affairs

888-990-AMRX (2679)

[email protected]

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Neurology Mental Health Health Pharmaceutical Health Insurance

MEDIA:

Logo

A10 Networks to Announce First Quarter 2025 Financial Results on May 1, 2025

SAN JOSE, Calif.–(BUSINESS WIRE)–
A10 Networks (NYSE: ATEN), a leading provider of secure application services and solutions, today announced that the company’s first quarter 2025 financial results will be released after the markets close on Thursday, May 1, 2025. Management will host a call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.

Interested parties may access the conference call by dialing (888) 506-0062 (toll-free) or (973) 528-0011 (international) and referencing access code: 977788.

A live audio webcast of the conference call will be accessible from the “Investor Relations” section of A10 Network’s website at investors.a10networks.com. The webcast will be archived for one year. A telephonic replay of the conference call will be available until May 15, 2025 and may be accessed by dialing (877) 481-4010 (toll-free) or (919) 882-2331 (international) and entering the passcode: 52288.

About A10 Networks

A10 Networks (NYSE: ATEN) provides security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments. Our 7000+ customers span global large enterprises and communications, cloud and web service providers who must ensure business-critical applications and networks are secure, available, and efficient. Founded in 2004, A10 Networks is based in San Jose, Calif. and serves customers globally. For more information, visit A10networks.com and follow us at A10Networks.

The A10 logo and A10 Networks are trademarks or registered trademarks of A10 Networks, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

Source: A10 Networks, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403359682/en/

Investor Contact:

Rob Fink or Tom Baumann

FNK IR

646.809.4048 / 646.349.6641

[email protected]

Brian Becker

Chief Financial Officer

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Communications Security Technology Mobile/Wireless Software Public Relations/Investor Relations

MEDIA:

Posted on April 3, 2025 8:04 am

PROG Holdings, Inc. to Release First Quarter 2025 Financial Results on April 23, 2025

PROG Holdings, Inc. to Release First Quarter 2025 Financial Results on April 23, 2025

SALT LAKE CITY–(BUSINESS WIRE)–PROG Holdings, Inc. (NYSE:PRG), the fintech holding company for Progressive Leasing, Vive Financial, Four Technologies, and Build, is scheduled to release financial results for the first quarter of 2025 on Wednesday, April 23, 2025 prior to the market open.

The company has also scheduled a live webcast for April 23, 2025 at 8:30 A.M. ET to discuss its financial results for the first quarter of 2025. The webcast can be accessed via the below link, or through the Events & Presentations section of the PROG Holdings investor relations website, https://investor.progholdings.com.

Webcast Link: https://edge.media-server.com/mmc/p/sm452hrq

About PROG Holdings, Inc.

PROG Holdings, Inc. (NYSE:PRG) is a fintech holding company headquartered in Salt Lake City, UT, that provides transparent and competitive payment options and inclusive consumer financial products. The Company owns Progressive Leasing, a leading provider of e-commerce, app-based, and in-store point-of-sale lease-to-own solutions, Vive Financial, an omnichannel provider of second-look revolving credit products, Four Technologies, provider of Buy Now, Pay Later payment options through its platform Four, and Build, provider of personal credit building products. More information on PROG Holdings’ companies can be found at https://www.progholdings.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250403352834/en/

Investor Contact

John A. Baugh, CFA

VP, Investor Relations

[email protected]

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Professional Services Payments Apps/Applications Technology Finance Fintech Banking

MEDIA:

Logo